Lung Cancer Treatment Shows Promise in Phase III Study
A new combination therapy demonstrated significant efficacy in patients with non-small cell lung cancer.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe new pharmaceutical research typically leads to meaningful improvements in patient health?
Kelun-Biotech released positive Phase III results for a drug combination targeting non-small cell lung cancer at the 2026 ESMO Congress. The study revealed that sacituzumab tirumotecan plus pembrolizumab reduced the risk of disease progression or death by 51%.
Why it matters
This clinical data offers a potential new treatment pathway for patients with driver gene-negative, PD-L1-negative non-squamous non-small cell lung cancer. The results represent a successful achievement of the study's primary endpoint for progression-free survival.
The study utilized a randomized sample of 455 patients, showing an objective response rate of 50.2% in the combination treatment group. Median duration of response reached 13.6 months, while the ADC maintained a drug-to-antibody-ratio of 7.4.
The players
Kelun-Biotech
This Chengdu-based biotechnology company focuses on the research and development of novel cancer therapies.
ESMO Congress
This annual international meeting brings together leading oncology professionals to share advancements in cancer research.
The New England Journal of Medicine
This peer-reviewed medical journal is one of the most cited and influential sources for clinical research findings.
MSD
Also known as Merck & Co. in the United States and Canada, this global pharmaceutical firm collaborates on drug development.
The details
The OptiTROP-Lung06 trial evaluated sacituzumab tirumotecan plus pembrolizumab against a control group receiving platinum-based doublet chemotherapy combined with pembrolizumab. Researchers utilized blinded independent central review to assess progression-free survival, noting lower incidences of Grade 3 or higher adverse events in the experimental group.
Timeline
May 2022: Kelun-Biotech licensed sac-TMT rights to MSD.
June 9, 2026: Data cut-off date for OptiTROP-Lung06 study.
October 25, 2026: Results presented at ESMO Congress and published.
The Big Picture
The presentation of these results at the ESMO Congress highlights the industry-wide focus on antibody-drug conjugates in lung cancer treatment. This study follows a pattern set by previous oncology research presented at this institution, showcasing the efficacy of novel combination therapies.
The clinical success of this combination therapy may eventually expand treatment options for patients diagnosed with non-small cell lung cancer. It could potentially lead to improved quality of life metrics due to the observed lower incidence of severe adverse events.
The takeaway
Advancements in targeted therapies like antibody-drug conjugates continue to change the standard of care for non-small cell lung cancer. Clinicians are now looking toward these combinations to replace more toxic traditional chemotherapy regimens.
Further reading
For more information on current clinical research, visit the Cancer section.
More information
View full details regarding the study and company developments at the Kelun-Biotech company information.
Live Poll
Do you believe new pharmaceutical research typically leads to meaningful improvements in patient health?
